Neovacs SA (FR:ALNEV) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Neovacs SA, a French biotech firm focusing on inflammatory and autoimmune diseases, has partnered with CNRS’s UTCBS to develop mRNA vaccine delivery methods for asthma treatment. The collaboration, which Neovacs will exclusively fund for 100 k€, aims to create lipid formulations for human and veterinary vaccines. The company is recognized by the CNRS for its R&D efforts in the field of active immunotherapy through its kinoid® technology platform.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.